Phase 2 study of fix dose rate gemcitabine plus S-1 with advanced biliary tract cancer refractory to standard dose rate gemcitabine.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer; Biliary tract disorders; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 01 Dec 2017 Results assessing safety and efficacy published in the Cancer Chemotherapy and Pharmacology
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.
- 06 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.